Purpose: Given the potential for improved outcomes, a phase I trial was initiated to develop a paclitaxel/cisplatin regimen that could be delivered every two weeks to women with newly diagnosed advanced ovarian cancer.
Summary
Purpose: Given the potential for improved outcomes, a phase I trial was initiated to develop a paclitaxel/cisplatin regimen that could be delivered every two weeks to women with newly diagnosed advanced ovarian cancer.
Patients and methods: From 1992 to 1994, 29 (28 eligible) patients were enrolled in a dose-seeking trial. All received 60 mg/m 2 of cisplatin preceded by paclitaxel infused over three hours. The paclitaxel dose was excalated from an initial level of 90 mg/m 2 by 10 mg/m 2 increments in successive cohorts of patients.
Results: At 120 mg/m 2 of paclitaxel, the dose-limiting toxicity was granulocytopenia which prevented retreatment on time. The recommended dose level was therefore paclitaxel 110 mg/m 2 infused over three hours with cisplatin 60 mg/m 2 , repeated bi-weekly for eight cycles.
Conclusion:
This bi-weekly schedule of paclitaxel/cisplatin provides no advantage in terms of dose-intensity nor total dose of paclitaxel in comparison to more common regimens given tri-weekly.
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Background
By 1992, front-line chemotherapy for women with advanced ovarian cancer was based upon cisplatin or carboplatin. It had been shown that cisplatin could be given bi-weekly, achieving a shorter overall treatment time and a higher dose-intensity [1] .
Additionally, paclitaxel had demonstrated activity in some patients with platin-resistant disease (2,3,4 subsequently reported as 5). A phase III trial of this drug (as a 24-hour infusion) administered tri-weekly with cisplatin had been initiated in newly diagnosed patients (the Gynecologic Oncology Group Study 111). Also, neutropenia was less if paclitaxel was given over three hours, and usually was resolving within two weeks [6] . Thus, it seemed feasible and potentially beneficial to combine these two agents in a bi-weekly schedule. We pursued this developmental objective in patients with newly diagnosed disease, hoping to establish dose levels for possible phase H/in studies.
Patients and methods

Patient population
Previously untreated women aged 18 to 65 with macroscopic residual epithelial ovarian cancer remaining at the completion of primary surgery, an ECOG performance status of 0 or 1, and near-normal laboratory parameters were eligible. All patients gave written informed consent. Excluded were those with low malignant potential rumors, pre-existing neuropathy or cardiac disease, another invasive malignancy or a concurrent serious medical condition.
Trial design
The objective was to determine the dose of paclitaxel that could be combined with a fixed dose (60 mg/m 2 ) of cisplatin given bi-weekly for eight cycles [1] . In a second-line setting, paclitaxel had been delivered in doses ranging from 135 to 175 mg/m 2 q 3w [6] (equivalent to 90 and 116 mg/m 2 q 2w). Thus we selected a starting dose of paclitaxel of 90 mg/m 2 , with subsequent dose-level increments of 10 mg/m 2 . A minimum of three evaluable patients were to be entered at each dose-level, with the subsequent level not opened until safety had been assured. No intrapatient dose escalation was undertaken. Premedications included dexamethasone, diphenhydramine, cimetidine, and ondansetron. A three-hour 'prehydration' preceded the three-hour paclitaxel infusion, followed by a three-hour cisplatin infusion, and finally a three-hour 'post-hydration' phase (details available on request).
In an effort to maintain treatment frequency, 'physiologic' endpoints of hematologic dose limiting toxicity (DLT) were employed [7] , specifically: retreatment was delayed until granulocytes were >0.75 x 10 two or more of six patients experienced DLT within the first two full cycles of therapy. The recommended dose was to be that one lower than the MTD. In general, toxiciu'es of >grade 3 would result in treatment discontinuation. Hemograms were performed on alternate days during cycles 1 and 2, then less frequently. A complete response required normalization of the CA 125.
Although toxic effects comprised the primary study endpoints, response, progression and survival information were recorded. (Table 1) Three centres enrolled 29 patients between November 1992 and October 1994, one patient was ineligible (performance status of > 1). Sixteen patients had disease which could be monitored for response. (Table 2) Four of 28 patients failed to complete treatment two went off-study at investigator discretion (one with grade 2 paclitaxel hypersensitivity at cycle 1, another with grade 2 neurotoxicity after six cycles), one had disease progression after four cycles, the fourth refused further treatment after six cycles.
Results
Patients
Treatment delivery
Toxicity
Four episodes of DLT were encountered, all consisting of granulocytopenia on day 14 of the first cycle which prevented retreatment on time. One event was seen in eight patients at the 100 mg/m 2 level, one in 10 at 110 mg/m 2 , and two in six at 120 mg/m 2 . Thus, this latter dose was the MTD.
Worst ever toxicity encountered during the full course of treatment is outlined in Table 3 . Platelet toxicity was minimal (5/27 with grade 1), anemia moderate (15/27 with grade 2). Re-hospitaHzation was not required. The non-hematologic toxicities were the anticipated side effects of the study agents and support medications.
Response and survival
Of the 16 patients with clinically evaluable disease, seven achieved a CR, three a PR, and one stable disease (five were not reassessed for response). One of the 12, enrolled without evaluable disease, progressed 
Conclusion
Paclitaxel combined with cisplatin can be given safely on a bi-weekly schedule to newly diagnosed patients with ovarian cancer. At the recommended dose of paclitaxel of 110 mg/m 2 and cisplatin 60 mg/m 2 , neither the dose intensity nor the potential total dose of paclitaxel with this regimen are greater than that achieved in a recently completed intergroup trial where doses of 175 mg/m 2 and 75 mg/m 2 , respectively, were given every three weeks (OV 10). This could be a disadvantage if paclitaxel dose-effects are important in primary treatment, as they have been shown to be in a retreatment setting [8] .
A similar study to ours has been completed in women with metastatic breast cancer [9] , which identified cisplatin 60 mg/m 2 with paclitaxel 90 mg/m 2 (over three hours) every two weeks as the recommended phase II doses in that setting. Notably, and despite the modest dose-intensity achieved, this was not only well tolerated but remarkably active (85% response rate) in a population exposed to prior anthracycline-based adjuvant treatment.
Thus despite an apparently reasonable response rate and acceptable toxicity, this bi-weekly regimen is unlikely to offer important advantages over the tri-weekly standard as first-line therapy for women with ovarian cancer. Unless the results from newer comparative trials show superior outcomes from differing doseschedules of these agents, the GOG regimen of paclitaxel 135 mg/m 2 over 24 hours with cisplatin 75 mg/ m 2 given tri-weekly [10] is preferred. The results of further studies designed to explore the dose-scheduleactivity interactions between these agents are awaited.
